explained | Nipah, a highly pathogenic paramyxovirus

The natural reservoir for the virus is the large fruit bats of the Pteropus genus. From here, it can be passed on to pigs that may become infected after eating fruit bitten by infected bats.

Story so far: Kerala has reported death from a case Kozhikode’s northern district brings back memories of chaos due to Nipah virus infection May-June 2018 When 18 confirmed cases were reported in the same district, of which 17 were laboratory-confirmed deaths. It is the high death rate associated with the virus that caused panic throughout the state and country and when it was controlled the state’s health surveillance system came in for praise, although, as it turned out, it was only one for the 2020 pandemic. There was a test-run. .

What do we know about the Nipah virus outbreak?

Human Nipah virus, as it is called, is classified as an “emerging zoonotic disease”, which means it can transfer to people after incubation in other species. It was first identified in a large outbreak of 276 cases in Malaysia and Singapore from September 1998–1999.

Prior to the 2018 Kerala outbreak, there have been several Nipah virus outbreaks with outbreaks in India, particularly in Siliguri and Nadia in West Bengal in 2001 and 2007. During the outbreak in Siliguri, 33 health workers and hospital visitors became ill after coming in contact with patients suffering from Nipah virus disease. At least 70 people died in the outbreak in these two districts. In the 2018 outbreak in Kerala, family of four The first person to confirm the infection succumbed to the viral disease.

How does Nipah virus originate and spread?

Nipah virus (NIV) is classified as a “highly pathogenic paramyxovirus” and requires the highest-grade facilities, called BS-IV, to handle the virus. The natural reservoir for the virus is the large fruit bats of the Pteropus genus. From here the virus can spread to pigs who can become infected after eating fruit bitten by infected bats.

Initial outbreaks were reported among pig breeders, while in Bangladesh it was suspected that the virus had jumped to humans who directly consumed fruits that may have been contaminated with bat saliva or urine. It takes 6-21 days for the virus to develop and manifest as a disease.

Drinking raw date palm juice contaminated with NiV and close physical contact with Nipah infected patients are believed to be the two main ways of spreading. Person-to-person transmission can occur by close physical contact, particularly through contact with body fluids.

Unlike in the case of the novel coronavirus, which is more airborne and can spread over great distances, the Nipah virus is not a very efficient spreader. Exposure to body fluids and respiratory droplets of an infected person, which is not expected to travel very far, is said to be the main source of spread which suggests that close family members in a household are most at risk with infection. Why is it said to be spreading among patients in hospital settings.

What are the symptoms of the disease and how is it diagnosed?

Fever, delirium, severe weakness, headache, shortness of breath, cough, vomiting, muscle pain, convulsions, diarrhea are the main associated symptoms. In infected people, Nipah virus causes severe disease characterized by inflammation of the brain (encephalitis) or respiratory diseases, which is why it is associated with high mortality. Due to the lethality of the virus, very few laboratories such as the Pune-based National Institute of Virology are equipped to isolate and confirm the virus.

Antibody tests that detect the presence of antibodies in the serum of the cerebrospinal fluid can be used to detect infection or the RNA of the virus can be detected from respiratory secretions, urine, or cerebrospinal fluid.

Does treatment exist?

There is currently no known treatment or vaccine available for people or animals. According to a fact sheet by the National Center for Disease Control, ribavirin, an antiviral, may have a role in reducing mortality in patients with encephalitis caused by Nipah virus disease.

The emphasis of treatment depends on the management of symptoms.

However, immunotherapeutic therapies (monoclonal antibody therapy) for the treatment of NiV infection are currently under development and evaluation. One such monoclonal antibody, m102.4, has completed phase 1 clinical trials and has been used on a compassionate basis. In addition, according to the US Centers for Disease Control, the antiviral treatment remdesivir has been effective in nonhuman primates when given as post-exposure prophylaxis. There are no approved vaccines or even test-vaccines as part of human trials for the virus.

.

Leave a Reply